Providers, trials, pharma and de-identified health data.
4 data products and services
540,000 interventional and observational trials harmonised from public registries worldwide, with phases, conditions, sponsors, site locations, enrolment and status history.
WAC list price changes, NADAC acquisition costs and FDA approval events for 24,000 US drug products and 110,000 NDC package codes, linked by ingredient and manufacturer.
2.6 million US physicians, nurse practitioners and healthcare organisations keyed by NPI, with specialties, practice locations, hospital affiliations and licence status.
Quarterly counts and allowed costs by procedure, diagnosis group, drug and 3-digit ZIP region from de-identified US claims, certified by expert determination with small cells suppressed.
Healthcare and life sciences data covers the reference and analytics datasets that pharma, medtech, payers, health systems and investors use to understand who delivers care, which treatments are in development, and how care is used and paid for. On DataStoa this group is limited to data that does not identify patients: professional directories, trial registries, drug and pricing data, and claims that have been de-identified and aggregated.
Start from the question. Commercial targeting and network analysis need provider data; pipeline and competitor work needs trial and pharma data; questions about volumes, costs and patient journeys need claims. Many projects combine them through shared keys such as provider identifiers, drug codes and trial IDs, so ask whether a provider already maps those keys for you.
Last reviewed on 11 Nov 2026
Healthcare provider dataGermanyOne-time deliveryDemo request
Describe the coverage, fields and delivery you need. Providers who sell it reply with proposals, and you choose who to talk to.
